{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T19:01:04Z","timestamp":1792004464910,"version":"4.4.0"},"reference-count":34,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T00:00:00Z","timestamp":1741305600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: In the current era of tailored therapy, biologics such as vedolizumab (VDZ) and ustekinumab (UST) are increasingly administered to inflammatory bowel disease (IBD) patients. The decision to discontinue biologics after side effects or a lack of response is usually simple, but the decision to stop treatment in patients in remission is more difficult: to date, no study has been conducted to investigate the effects of VDZ or UST withdrawal. Our study aims to investigate the rates and predictors of relapse of IBD after the discontinuation of VDZ and UST during a well-controlled disease phase and to evaluate the response to retreatment. Methods: In this observational, multicenter, retrospective study, we included IBD patients who discontinued VDZ or UST during a well-controlled disease phase after at least 1 year of treatment. We collected demographic and clinical data for each patient at the time of discontinuation and at follow-up visits. Results: We included 36 IBD patients from 5 different centers; 80.0%, 58.5%, and 48.3% of patients maintained clinical remission at 12, 24, and 48 months after discontinuation, respectively. Crohn\u2019s disease (CD) patients were more likely to maintain remission than ulcerative colitis (UC) patients at 48 months (70.0% vs. 40.0%). No predictors of relapse were identified, but UC patients had a higher risk of early relapse than CD patients (HR = 3.23); 81.3% of retreated IBD patients achieved clinical remission after induction and at 12 months. Conclusions: No predictors of disease relapse after treatment discontinuation were identified. Half of the patients had a relapse within 48 months after discontinuation, but most of them achieved clinical remission after retreatment.<\/jats:p>","DOI":"10.3390\/jcm14061793","type":"journal-article","created":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T04:29:59Z","timestamp":1741321799000},"page":"1793","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Relapse Rates and Predictors for Relapse in Ulcerative Colitis and Crohn\u2019s Disease Patients After Discontinuation of Vedolizumab or Ustekinumab: The REVEUS Study"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9064-3434","authenticated-orcid":false,"given":"Alessandro","family":"Massano","sequence":"first","affiliation":[{"name":"Gastroenterology Unit, Department of Surgery, Oncology and Gastroenterology, Azienda Ospedale Universit\u00e0 Padova, University of Padua, 35121 Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3187-2894","authenticated-orcid":false,"given":"Edoardo Vincenzo","family":"Savarino","sequence":"additional","affiliation":[{"name":"Gastroenterology Unit, Department of Surgery, Oncology and Gastroenterology, Azienda Ospedale Universit\u00e0 Padova, University of Padua, 35121 Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5677-2534","authenticated-orcid":false,"given":"Simone","family":"Saibeni","sequence":"additional","affiliation":[{"name":"IBD Centre, Gastroenterology Unit, Rho Hospital, ASST Rhodense, 20017 Rho, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Bezzio","sequence":"additional","affiliation":[{"name":"IBD Centre, IRCCS Humanitas Research Hospital, 20089 Rozzano, Italy"},{"name":"Department of Biomedical Sciences, Humanitas University, 20072 Pieve Emanuele, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8653-1790","authenticated-orcid":false,"given":"Lorenzo","family":"Bertani","sequence":"additional","affiliation":[{"name":"Azienda Ospedaliera Universitaria Pisana, 56126 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0529-9481","authenticated-orcid":false,"given":"Gian Paolo","family":"Caviglia","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, University of Turin, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Vernero","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, University of Turin, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7245-4445","authenticated-orcid":false,"given":"Angelo","family":"Armandi","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, University of Turin, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9421-3087","authenticated-orcid":false,"given":"Davide Giuseppe","family":"Ribaldone","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, University of Turin, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,3,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Actis, G.C., Pellicano, R., Fagoonee, S., and Ribaldone, D.G. (2019). History of Inflammatory Bowel Diseases. J. Clin. Med., 8.","DOI":"10.3390\/jcm8111970"},{"key":"ref_2","first-page":"13","article-title":"Immunopathogenesis of IBD: Current state of the art","volume":"13","author":"Fiocchi","year":"2015","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3748\/wjg.v20.i1.91","article-title":"Inflammatory bowel disease: Pathogenesis","volume":"20","author":"Zhang","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"25","DOI":"10.4110\/in.2017.17.1.25","article-title":"Pathogenesis of Inflammatory Bowel Disease and Recent Advances in Biologic Therapies","volume":"17","author":"Kim","year":"2017","journal-title":"Immune Netw."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as Induction and Maintenance Therapy for Crohn\u2019s Disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","article-title":"Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1053\/j.gastro.2018.06.035","article-title":"Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients with Crohn\u2019s Disease","volume":"155","author":"Rutgeerts","year":"2018","journal-title":"Gastroenterology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"159452","DOI":"10.1177\/17562848231159452","article-title":"Is there an optimal sequence of biologic therapies for inflammatory bowel disease?","volume":"16","author":"Bressler","year":"2023","journal-title":"Ther. Adv. Gastroenterol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"258372","DOI":"10.1177\/17562848241258372","article-title":"Long-term outcomes and predictors of vedolizumab persistence in ulcerative colitis","volume":"17","author":"Gros","year":"2024","journal-title":"Ther. Adv. Gastroenterol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"174953","DOI":"10.1177\/17562848231174953","article-title":"Long-term outcomes of vedolizumab in inflammatory bowel disease: The Swedish prospective multicentre SVEAH extension study","volume":"16","author":"Visuri","year":"2023","journal-title":"Ther. Adv. Gastroenterol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"910","DOI":"10.14309\/ajg.0000000000002621","article-title":"Efficacy and Safety of Ustekinumab for Ulcerative Colitis Through 4 Years: Final Results of the UNIFI Long-Term Maintenance Study","volume":"119","author":"Afif","year":"2023","journal-title":"Am. J. Gastroenterol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Mocci, G., Tursi, A., Scaldaferri, F., Napolitano, D., Pugliese, D., Capobianco, I., Bartocci, B., Blasi, V., Savarino, E.V., and Maniero, D. (2024). Long-Term Effectiveness and Safety of Ustekinumab in Crohn\u2019s Disease: Results from a Large Real-Life Cohort Study. J. Clin. Med., 13.","DOI":"10.3390\/jcm13237192"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","article-title":"ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment","volume":"16","author":"Raine","year":"2021","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/ecco-jcc\/jjz180","article-title":"ECCO Guidelines on Therapeutics in Crohn\u2019s Disease: Medical Treatment","volume":"14","author":"Torres","year":"2019","journal-title":"J. Crohn's Colitis"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.12998\/wjcc.v12.i10.1718","article-title":"Discontinuation of therapy in inflammatory bowel disease: Current views","volume":"12","author":"Kumric","year":"2024","journal-title":"World J. Clin. Cases"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1159\/000531497","article-title":"Real-World Effectiveness and Risk Factors for Discontinuation of Ustekinumab in Ulcerative Colitis","volume":"8","author":"Uchida","year":"2023","journal-title":"Inflamm. Intest. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"otaa074","DOI":"10.1093\/crocol\/otaa074","article-title":"Patient-Preferences Favoring Treatment Discontinuation Are Reduced with Vedolizumab and Ustekinumab Compared with TNF Antagonists in Inflammatory Bowel Disease","volume":"2","author":"Kumar","year":"2020","journal-title":"Crohn's Colitis 360"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S2468-1253(22)00385-5","article-title":"Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): A multicentre, open-label, randomised controlled trial","volume":"8","author":"Louis","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"752","DOI":"10.5009\/gnl20233","article-title":"Long-term Outcomes after the Discontinuation of Anti-Tumor Necrosis Factor-\u03b1 Therapy in Patients with Inflammatory Bowel Disease under Clinical Remission: A Korean Association for the Study of Intestinal Disease Multicenter Study","volume":"15","author":"Song","year":"2021","journal-title":"Gut Liver"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/ajg.2016.569","article-title":"Evolution After Anti-TNF Discontinuation in Patients with Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study","volume":"112","author":"Casanova","year":"2017","journal-title":"Am. J. Gastroenterol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/j.cgh.2016.05.044","article-title":"Discontinuation of Infliximab in Patients with Ulcerative Colitis Is Associated with Increased Risk of Relapse: A Multinational Retrospective Cohort Study","volume":"14","author":"Fiorino","year":"2016","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S2468-1253(21)00062-5","article-title":"Discontinuation of infliximab in patients with ulcerative colitis in remission (HAYABUSA): A multicentre, open-label, randomised controlled trial","volume":"6","author":"Kobayashi","year":"2021","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1093\/ecco-jcc\/jjaa005","article-title":"Maintenance of Remission Among Patients with Inflammatory Bowel Disease After Vedolizumab Discontinuation: A Multicentre Cohort Study","volume":"14","author":"Martin","year":"2020","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1016\/j.cgh.2021.03.037","article-title":"Prediction of Relapse After Anti\u2013Tumor Necrosis Factor Cessation in Crohn\u2019s Disease: Individual Participant Data Meta-analysis of 1317 Patients From 14 Studies","volume":"20","author":"Pauwels","year":"2021","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.cgh.2017.09.061","article-title":"Outcomes 7 Years After Infliximab Withdrawal for Patients with Crohn\u2019s Disease in Sustained Remission","volume":"16","author":"Reenaers","year":"2017","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1053\/j.gastro.2015.08.055","article-title":"Systematic Review of Effects of Withdrawal of Immunomodulators or Biologic Agents from Patients with Inflammatory Bowel Disease","volume":"149","author":"Torres","year":"2015","journal-title":"Gastroenterology"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.cgh.2024.06.049","article-title":"The Cost of Inflammatory Bowel Disease Care\u2014How to Make it Sustainable","volume":"23","author":"Burisch","year":"2024","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1093\/ecco-jcc\/jjy113","article-title":"ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications","volume":"13","author":"Maaser","year":"2019","journal-title":"J. Crohn's Colitis"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1097\/01.MIB.0000215091.77492.2a","article-title":"Predicting the Crohn\u2019s disease activity index from the harvey-bradshaw index","volume":"12","author":"Best","year":"2006","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1002\/ibd.20520","article-title":"Use of the noninvasive components of the mayo score to assess clinical response in Ulcerative Colitis","volume":"14","author":"Lewis","year":"2008","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1093\/ibd\/izx098","article-title":"Stopping Biologics in IBD\u2014What Is the Evidence?","volume":"24","author":"Louis","year":"2018","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/apt.13276","article-title":"Systematic review: Factors associated with relapse of inflammatory bowel disease after discontinuation of anti-TNF therapy","volume":"42","author":"Gisbert","year":"2015","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1007\/s10238-023-00994-6","article-title":"Relapse rates after withdrawal versus maintaining biologic therapy in IBD patients with prolonged remission","volume":"23","author":"Stoker","year":"2023","journal-title":"Clin. Exp. Med."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/6\/1793\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:48:48Z","timestamp":1760028528000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/6\/1793"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,7]]},"references-count":34,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["jcm14061793"],"URL":"https:\/\/doi.org\/10.3390\/jcm14061793","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,7]]}}}